Author

Marisa Iborra

IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION
IN HIGHLY REFRACTORY ULCERATIVE COLITIS PATIENTS, USTEKINUMAB IS A GOOD THERAPEUTIC OPTION

Marisa Iborra  et al.

LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA
LONG-TERM TRENDS IN TARGETED THERAPIES USAGE IN INFLAMMATORY BOWEL DISEASE: TRENDY STUDY OF ENEIDA

Marisa Iborra  et al.

SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA
SAFETY AND LONG-TERM PERSISTENCE OF BIOLOGICAL TREATMENTS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. DIFFERENCES BETWEEN WOMEN AND MEN: SEXEII STUDY OF ENEIDA

Marisa Iborra  et al.

EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
EFFECTIVENESS AND SAFETY OF USTEKINUMAB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

Marisa Iborra  et al.

IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52
IN PATIENTS WITH CROHN'S DISEASE, FECAL CALPROTECTIN DROP-SLOPE DURING INDUCTION WITH USTEKINUMAB CAN AFFECT ITS LEVELS AND DISCRIMINATE THE NEED FOR INTENSIFICATION AT WEEK 52

Marisa Iborra  et al.

COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY
COMPARISON OF THE EFFICACY OF A SECOND INTRAVENOUS OR SUBCUTANEOUS ANTI-TNF IN THE TREATMENT OF ULCERATIVE COLITIS. REAL-WORLD DATA FROM THE ENEIDA REGISTRY

Marisa Iborra  et al.

CELLULAR IMMUNE RESPONSE TRIGGERED BY GRANULOCYTOAPHERESIS IN ULCERATIVE COLITIS PATIENTS UNDER BIOLOGICAL TREATMENT
CELLULAR IMMUNE RESPONSE TRIGGERED BY GRANULOCYTOAPHERESIS IN ULCERATIVE COLITIS PATIENTS UNDER BIOLOGICAL TREATMENT

Marisa Iborra  et al.

REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
REAL WORLD EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN CROHN’S DISEASE WHEN USED AS A FIRST BIOLOGIC OR AFTER FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Marisa Iborra  et al.

OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)
OBSERVATIONAL STUDY ON THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB IN AN ULCERATIVE COLITIS POPULATION COMPRISED BY BIO-NAÏVE PATIENTS AND PATIENTS WITH FAILURE OF ONE PREVIOUS ANTI-TNF (EVOLVE-IB STUDY)

Marisa Iborra  et al.

USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY
USE OF MYCOPHENOLATE MOFETIL IN INFLAMMATORY BOWEL DISEASE: RESULTS FROM THE ENEIDA REGISTRY

Marisa Iborra  et al.

RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY
RISK FACTORS AND LONG-TERM OUTCOMES ASSOCIATED WITH IMMUNOSUPPRESSION IN PATIENTS WITH ULCERATIVE PROCTITIS: RESULTS FROM THE ENEIDA REGISTRY

Marisa Iborra  et al.

INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU
INFLAMMATORY BOWEL DISEASE (IBD) AND IMMUNOSUPPRESSION DO NOT WORSEN THE PROGNOSIS OF COVID-19. RESULTS FROM THE ENEIDA PROJECT OF GETECCU

Marisa Iborra  et al.

COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY
COMORBIDITIES AND EPIDEMIOLOGICAL RISK FACTOR BUT NOT IMMUNOSUPPRESSIVE THERAPIES INCREASE THE RISK OF COVID-19 IN INFLAMMATORY BOWEL DISEASE (IBD): AN ENEIDA-BASED, CASE-CONTROL STUDY

Marisa Iborra  et al.

Item 1 - 13 / 13
1